SecBot SecBot

GRTX

Galera Therapeutics, Inc.
OTC· Pharmaceutical Preparations· Inc. DE· CIK 0001563577 Biotech & Drug Discovery
—
Next earnings
Nov 11
in 16 days
Short interest
7.4K
+9.6%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
Filing reports
12
analyzed by SecBot
SecBot read BEARISH 3 reports · 90 days
Balance 2 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next Earnings date, Nov 11, 2026
Strongest BEARISH Galera Therapeutics completed its merger with Obsidian Therapeutics (formerly Gazelle Parent) on August 3…
All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • Short sellersSTEADY

    Short interest +9.6% to 7.4K shares. 1.0 days to cover.

The Street

last action Aug 2023
Recent actions
DateFirmActionRating
Aug 29, 2023Citigroup
MAINTAIN
MAINTAINNeutral
Aug 16, 2023HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Aug 10, 2023Piper Sandler
DOWNGRADE
DOWNGRADENeutral
Jul 17, 2023HC Wainwright & Co.
REITERATE
REITERATEBuy
Mar 22, 2023HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Feb 21, 2023Piper Sandler
INITIATE
INITIATEOverweight
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
GRTX Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Aug 11, 2026
Earnings date
GRTX Q2 2026 Earnings Scheduled — 2026-08-11
May 13, 2026
Earnings date
GRTX Q1 2026 Earnings Scheduled — 2026-05-13
Apr 14, 2026
M&A
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
CAMBRIDGE, Mass. and MALVERN, Pa., April 14, 2026 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage…
Mar 30, 2026
Earnings date
GRTX Q4 2025 Earnings After Market Close — 2026-03-30

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 3, 2026
Alleva Lawrence M
Director
TO ISSUER40 sh
Aug 3, 2026
FRIEDMAN MICHAEL R.
Director
TO ISSUER41,631 sh
Aug 3, 2026
Alleva Lawrence M
Director
TO ISSUER240 sh
Aug 3, 2026
Alleva Lawrence M
Director
TO ISSUER11 sh
Aug 3, 2026
Sussman Joel F.
Chief Accounting Officer
TO ISSUER10,000 sh
Aug 3, 2026
FRIEDMAN MICHAEL R.
Director
TO ISSUER480 sh
Aug 3, 2026
LOKAY KEVIN G
Director
TO ISSUER240 sh
Aug 3, 2026
CHANG NANCY T
Director
TO ISSUER47,434 sh

Earnings setup

Estimates
Nov 11
reports in 16 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Jun 30, 2026
7,365
shares short
+9.6%
vs prior settlement
1.0
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 11, 2026 Earnings calendar
GRTX Q2 2026 Earnings Scheduled — 2026-08-11
Aug 10, 2026 SEC
Galera Therapeutics, Inc.'s registration statement on Form POS AM (File No. 333-251061) was declared effective by the…
EFFECT — Impact 6/10
Aug 4, 2026 SEC
Galera Therapeutics filed a Form 15-12G to terminate registration of its common stock under Section 12(g) following…
15-12G — Impact 4/10
Aug 3, 2026 SEC
Galera Therapeutics completed its merger with Obsidian Therapeutics (formerly Gazelle Parent) on August 3, 2026…
8-K — Impact 8/10
Aug 3, 2026 Insider
Alleva Lawrence M disposed of 40 shares
Director
Aug 3, 2026 Insider
FRIEDMAN MICHAEL R. disposed of 41,631 shares
Director
Aug 3, 2026 Insider
Alleva Lawrence M disposed of 240 shares
Director
Apr 14, 2026 Press
Galera Therapeutics (GRTX) is merging with private biotech Obsidian Therapeutics in an all-stock transaction, with the…
Impact 7/10

SecBot reports

12 filings · 1 press release · 2 bullish · 4 bearish · 1 mixed · 5 neutral
All GRTX filing & press-release reports (13)